Pfizer's RA drug Xeljanz fails to win EU panel support

04/26/2013 | PharmaTimes (U.K.) · Reuters

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended against approving Pfizer's rheumatoid arthritis drug Xeljanz, or tofacitinib. The drug improved patients' physical function and RA symptoms but it failed to sufficiently demonstrate "a consistent reduction in disease activity and structural damage to joints," the committee said. Pfizer plans to appeal the recommendation.

View Full Article in:

PharmaTimes (U.K.) · Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA